» Articles » PMID: 1918136

Metastatic Behavior of Human Melanoma Cell Lines in Nude Mice Correlates with Urokinase-type Plasminogen Activator, Its Type-1 Inhibitor, and Urokinase-mediated Matrix Degradation

Overview
Journal J Cell Biol
Specialty Cell Biology
Date 1991 Oct 1
PMID 1918136
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Five out of six human melanoma cell lines tested were able to degrade in vitro a smooth muscle cell extracellular matrix in a plasmin-dependent way. In three of these five cell lines, this process was mediated by tissue-type plasminogen activator (t-PA) and in the other two cell lines by urokinase-type plasminogen activator (u-PA). All melanoma cell lines produced t-PA mRNA and protein, whereas only the two cell lines showing u-PA-mediated matrix degradation produced u-PA mRNA and protein. These latter cell lines also produced plasminogen activator inhibitor type-1 (PAI-1) and type-2 (PAI-2) mRNA and protein. u-PA receptor (u-PA-R) mRNA and binding of radiolabeled u-PA was found in all melanoma cell lines. The metastatic capacity of these cell lines was studied in nude mice. All cell lines were able to develop primary tumors at the subcutaneous inoculation site. The production of plasminogen activators, their inhibitors and urokinase receptor by subcutaneous tumors corresponded with the production by the parental cell lines in vitro. The two u-PA and PAI-1 producing cell lines showed the highest frequency to form spontaneous lung metastases after subcutaneous inoculation, whereas five of the six cell lines formed lung colonies after intravenous inoculation. In conclusion, u-PA mediated matrix degradation in vitro and production of u-PA and PAI-1 by human melanoma cell lines correlated with their ability to form spontaneous lung metastasis in nude mice. No correlation was found with the ability to form lung colonies after intravenous injection. These findings suggest a role for u-PA and PAI-1 in a relatively early stage of melanoma metastasis.

Citing Articles

Exosomes produced by melanoma cells significantly influence the biological properties of normal and cancer-associated fibroblasts.

Strnadova K, Pfeiferova L, Prikryl P, Dvorankova B, Vlcak E, Frydlova J Histochem Cell Biol. 2021; 157(2):153-172.

PMID: 34837514 PMC: 8847298. DOI: 10.1007/s00418-021-02052-2.


Interpretable deep learning uncovers cellular properties in label-free live cell images that are predictive of highly metastatic melanoma.

Zaritsky A, Jamieson A, Welf E, Nevarez A, Cillay J, Eskiocak U Cell Syst. 2021; 12(7):733-747.e6.

PMID: 34077708 PMC: 8353662. DOI: 10.1016/j.cels.2021.05.003.


Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo.

de Jong G, Bartels L, Kedde M, Verdegaal E, Gillissen M, Levie S Cancer Immunol Immunother. 2020; 70(6):1569-1581.

PMID: 33225419 PMC: 10992524. DOI: 10.1007/s00262-020-02780-9.


Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells.

Ragone C, Minopoli M, Ingangi V, Botti G, Fratangelo F, Pessi A J Exp Clin Cancer Res. 2017; 36(1):180.

PMID: 29216889 PMC: 5721612. DOI: 10.1186/s13046-017-0650-x.


Dynamic Fluorescence Microscopy of Cellular Uptake of Intercalating Model Drugs by Ultrasound-Activated Microbubbles.

Lammertink B, Deckers R, Derieppe M, De Cock I, Lentacker I, Storm G Mol Imaging Biol. 2017; 19(5):683-693.

PMID: 28213832 PMC: 5574961. DOI: 10.1007/s11307-016-1042-x.


References
1.
Behrendt N, Ronne E, Ploug M, Petri T, Lober D, Nielsen L . The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J Biol Chem. 1990; 265(11):6453-60. View

2.
Cubellis M, Andreasen P, Ragno P, Mayer M, Dano K, Blasi F . Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. Proc Natl Acad Sci U S A. 1989; 86(13):4828-32. PMC: 297508. DOI: 10.1073/pnas.86.13.4828. View

3.
Quax P, Van Leeuwen R, Verspaget H, Verheijen J . Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines. Cancer Res. 1990; 50(5):1488-94. View

4.
Cubellis M, Wun T, Blasi F . Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J. 1990; 9(4):1079-85. PMC: 551782. DOI: 10.1002/j.1460-2075.1990.tb08213.x. View

5.
Ellis V, Wun T, Behrendt N, Ronne E, Dano K . Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J Biol Chem. 1990; 265(17):9904-8. View